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Abstract
The prion consists essentially of PrP(Sc), a misfolded and aggregated conformer of the cellular protein
PrP(C). Whereas PrP(C) deficient mice are clinically healthy, expression of PrP(C) variants lacking its
central domain (PrP(DeltaCD)), or of the PrP-related protein Dpl, induces lethal neurodegenerative
syndromes which are repressed by full-length PrP. Here we tested the structural basis of these
syndromes by grafting the amino terminus of PrP(C) (residues 1-134), or its central domain (residues
90-134), onto Dpl. Further, we constructed a soluble variant of the neurotoxic PrP(DeltaCD) mutant that
lacks its glycosyl phosphatidyl inositol (GPI) membrane anchor. Each of these modifications abrogated
the pathogenicity of Dpl and PrP(DeltaCD) in transgenic mice. The PrP-Dpl chimeric molecules, but not
anchorless PrP(DeltaCD), ameliorated the disease of mice expressing truncated PrP variants. We
conclude that the amino proximal domain of PrP exerts a neurotrophic effect even when grafted onto a
distantly related protein, and that GPI-linked membrane anchoring is necessary for both beneficial and
deleterious effects of PrP and its variants.
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Abstract
The prion consists essentially of PrPSc, a misfolded and aggregated conformer of the cellular protein PrPC. Whereas PrPC
deficient mice are clinically healthy, expression of PrPC variants lacking its central domain (PrPDCD), or of the PrP-related
protein Dpl, induces lethal neurodegenerative syndromes which are repressed by full-length PrP. Here we tested the
structural basis of these syndromes by grafting the amino terminus of PrPC (residues 1–134), or its central domain (residues
90–134), onto Dpl. Further, we constructed a soluble variant of the neurotoxic PrPDCD mutant that lacks its glycosyl
phosphatidyl inositol (GPI) membrane anchor. Each of these modifications abrogated the pathogenicity of Dpl and PrPDCD
in transgenic mice. The PrP-Dpl chimeric molecules, but not anchorless PrPDCD, ameliorated the disease of mice expressing
truncated PrP variants. We conclude that the amino proximal domain of PrP exerts a neurotrophic effect even when grafted
onto a distantly related protein, and that GPI-linked membrane anchoring is necessary for both beneficial and deleterious
effects of PrP and its variants.
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Introduction
PrPSc is the main constituent of prions [1], the infectious agents
causing transmissible spongiform encephalopathies (TSE). PrPSc is an
aggregated andmisfolded isoform of the cellular prion protein PrPC [2]
which is expressed in a broad range of tissues of most vertebrates [3].
Nascent PrPC is exported to the lumen of the endoplasmic reticulum,
deprived of its amino terminal signal sequence, glycosylated at two
asparagine residues, and endowed with a GPI moiety which anchors it
to the outer cell surface. Ablation of the Prnp gene, which encodes
PrPC, abrogates prion replication [4] and toxicity [5]. Prnpo/o mice
enjoy a normal life expectancy [6], but suffer from subtle neurological
phenotypes [7] whose molecular basis has remained elusive [8].
Transgenic expression of amino proximally truncated PrPC
mutants (PrPDCD, PrPDE and PrPDF, henceforth collectively
termed DPrP) causes early-onset ataxia and white-matter degen-
eration (Fig. 1A). Toxicity appears to correlate with partial or
complete deletions of the conserved PrP central domain (CD,
residues 94–134) [9,10,11] which bridges the flexible amino
proximal tail and the globular carboxy proximal domain [12].
Another neurotoxic phenotype was detected in compound-
heterozygous Prnpo/ZHII mice and in homozygous PrnpZHII/ZHII mice
[13] whose PrnpZHII allele leads to ectopic expression of the PrPC-
related protein Dpl [14,15,16,17]. Neuronal expression of Dpl in
Tg(Dpl) or Tg(N-Dpl) mice induces ataxia within 40–60 days [18,19].
Despite 80% amino acid sequence dissimilarities [14], the overall 3D
structure of Dpl is similar to that of PrPC (Fig. 1B) and includes an
unstructured amino proximal tail, a globular three-helix domain [20],
and a GPI anchor. However, Dpl is physiologically not expressed in
the adult nervous system [21] and, importantly, lacks any sequences
comparable to the CD. Therefore, Dpl resembles the neurotoxic
DPrP mutants. What is more, the toxicity of both Dpl and DPrP is
counteracted by co-expression of full-length PrPC [9,10,18,22,23],
implying that it exploits common molecular pathways.
We reported previously that the removal of just the CD domain
confers dramatic neurotoxicity to PrP. This suggests that the
toxicity of Dpl may also result from the absence of a CD-like
domain. Here, we tested this hypothesis by transgenic expression
of two chimeric proteins, PrP_Dpl (residues 1–65 of Dpl replaced
by residues 1–133 of PrP) and CD_Dpl (residues 90–133 of PrP
inserted between residues 65 and 66 of Dpl). Transgenic mice
expressing these proteins did not develop any clinical phenotypes.
Additionally, coexpression of PrP_Dpl or of CD_Dpl ameliorated
the clinical syndromes and prolonged the life expectancy of mice
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expressing neurotoxic DPrP mutants, in agreement with a previous
report [24]. Since PrP is thought to be involved in signal
transduction, we tested whether the toxicity of CD-deficient PrP
mutants (PrPDCD) may require localization to membrane lipid
rafts. Indeed, removal of the GPI addition signal from PrPDCD
prevents its neurotoxic effects.
Results
Transgenic mice expressing chimeric PrP-Dpl proteins
and PrPDCDs
All chimeric mutants of Dpl and PrP described here are based
on the ‘half-genomic’ pPrPHG backbone [25] whose expression
Figure 1. PrP and Dpl genes, chimeric constructs, and transgenic mice. (A) Schematic drawing of the deletion mutants utilized for
generation of transgenic mice, and comparison to full-length wild-type PrPC and Dpl. (B) Comparison of the structures of the globular carboxy
terminal domains of murine PrP (left) and Dpl (right) (C–F) Hydrophobicity plots of wild-type murine PrP (C); wild-type murine Dpl (D); PrP_Dpl (E)
and CD_Dpl (F). PrP and Dpl sequences are drawn in blue and red, respectively. SP: secretory signal peptide, cleaved after sorting of the precursor to
endoplasmic reticulum. repeats: five repeats of eight amino acids. CC: charge cluster. HC: hydrophobic core. CD: central domain. H1–3: a-helix 1, 2,
3 of the globular carboxy proximal domain. MA: membrane anchor of precursor protein, replaced during maturation with glycosyl phosphatidyl
inositol anchor. The symbol indicates the epitopes recognized by the monoclonal mouse antibodies POM1, POM3, POM11, and E2.
doi:10.1371/journal.pone.0006707.g001
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pattern has been recently studied in detail [26]. This construct
contains a redacted murine Prnp gene which lacks intron#2 and is
flanked by 6 and 2.2 kb of 59 and 39 genomic regions, respectively.
Neuronal expression of Dpl leads to ataxia, neuronal loss and
demyelinating neuropathy [17,18,19,22] while most of the toxicity
of truncated PrP can be assigned to the lack of the central domain
CD (residues 94–134) [10]. If the absence of a CD-like domain
were responsible for its toxicity, addition of domains containing
the CD region of PrP might detoxify Dpl.
We constructed CD_Dpl, a chimeric fusion protein consisting of
codons 90–133 of mouse Prnp inserted between codons 65 and 66
of Prnd (Fig. 1A, F). This particular insertional position was chosen
because hydrophobicity comparisons suggested that the resulting
chimeric protein would resemble wild-type PrP (Fig. 1C–D). In a
second construct termed PrP_Dpl, the amino terminus of PrP
comprising codons 1–133 was fused to the carboxy terminus of
Dpl comprising codons 66–179 (Fig. 1A; E). Pronuclear injection
was performed into Prnp+/o zygotes resulting from a cross between
Prnpo/o and wild-type (wt) C57BL/6N mice giving rise to
transgenic founders on a Prnp+/o background (henceforth termed
PrP
z=o
PrP Dpl, PrP
o=o
PrP Dpl, PrP
z=o
CD Dpl and PrP
o=o
CD Dpl with superscripts
defining the Prnp allelic status and subscripts denoting the
respective hemizygous transgenes).
PrP and Dpl are tethered to the cell membrane by a C-terminal
GPI anchor. PrP has been proposed to act as a signal transducer
acting on various signaling pathways [9,10,27,28,29,30], and in
this context it was speculated that PrPDCD toxicity may require
membrane localization. To test this hypothesis, we introduced two
point mutations at codons 232 and 233 (original mouse
numbering) of the half-genomic construct PrPDCD [10], resulting
in two in-frame stop codons. This prevents the translation of the
carboxy terminal hydrophobic membrane anchoring domain of
the precursor protein (see Fig. 1A), resulting in a secreted PrP
mutant termed PrPDCDs. Because of the possible toxicity of the
transgene, pronuclear injection was performed into hybrid
B6D2F1 Prnp+/+ zygotes to generate PrP
z=z
DCDs (shorthand as above)
transgenic mice. The latter mice were predicted to be viable due to
the coexpression of wild-type PrP.
CD_Dpl founder mice #1070, #1071 and #1073, as well as
PrP_Dpl founder mice #1023, #1024, #1025 and #1026 and
PrPDCDs founder mice #36, #37, #38, #39, #40, #41, #42,
#43 all exhibited undistorted Mendelian transmission of the
transgene when backcrossed to Prnpo/o mice. Transgenic lines
were named according to the serial number of their founders. F2
generation mice were screened for transgenic integration and
expression. One CD_Dpl line (Tg1071), two PrP_Dpl lines
(Tg1025 and Tg1026) and two PrPDCDs lines (Tg40 and Tg42)
displayed easily detectable protein expression and were chosen for
further analysis (Table 1, Fig. S1, Fig. 2A–C). Quantitative PCR
using primers complementary to the common CD sequence
(CD_Dpl and PrP_Dpl) or to the 39-end of the coding region
(PrPDCDs) showed high copy numbers per genome in all transgenic
lines, resulting in higher mRNA levels for Prnp in wt mice or Dpl in
PrnpNgsk/Ngsk mice (Table 1, Fig. S1).
Western blots with monoclonal antibody POM3, whose linear
epitope was mapped to amino acid residues 95–105 of PrPC [31],
revealed significant expression of PrP_Dpl chimeras (2–3 times
higher compared to PrP in wt C57BL/6 mice) and of CD_Dpl (5-
fold higher than wt C57BL/6 mice; Table 1 and Fig. 2A, C). The
expression of CD_Dpl was similar to that of Dpl in PrnpNgsk/Ngsk
mice, whereas PrP_Dpl levels were lower (Fig. 2A, C). The
microanatomical distribution of the transgenic proteins resembled
that of PrPC (Fig. 2G–N). Western blots of brain homogenates
with monoclonal antibody POM11, whose epitope encompasses
amino acids 64–72 and 72–80 [10,31], revealed significant
expression of PrPDCDs (20–30% of wt C57BL/6 mice, Table 1
and Fig. 2B–C).
The levels of PrPDCDs in brains of both transgenic lines Tg40
and Tg42 was similar to that of Tg1046 PrPDCD [10] (Fig. 2B, C)
and paralleled the measured amount of mRNA (Fig. S1). PrPDCDs
showed a higher electrophoretic mobility than PrPDCD by 2–3
kDa, indicative of the missing GPI anchor.
Upon PNGase-F treatment, the complex banding pattern of
PrP_Dpl, CD_Dpl, PrPC, PrPDCDs, and PrPDCD was reduced to
one single band of lower molecular weight (Fig. 2A–B), suggesting
that these proteins were N-glycosylated. The strong reducing
conditions prior to PNGase-F treatment prevented recognition of
Dpl by anti-Dpl antibody (data not shown). suggesting that this
antibody recognizes a discontinuous C-terminal epitope destroyed
by reduction of the two disulfide bridges of Dpl. Milder
pretreatment resulted in partial deglycosylation of Dpl (Fig. 2A,
arrowhead); under these conditions CD_Dpl extracts gave rise to
two additional bands, which may indicate posttranslational
cleavage (Fig. 2A, arrowhead). PrP_Dpl extracts did not show
this phenomenon.
We then prepared detergent-resistant membranes (DRMs) from
wild-type, PrP_Dpl and CD_Dpl, (Fig. 2D), PrPDCDs, anchorless
PrPs, and PrPDCD brains (Fig. 2E) in the presence or absence of
PrPC. The buoyancy of PrP_Dpl, CD_Dpl, and PrPDCD was
similar to that of PrPC and flotillin (Fig. 2D–E), suggesting that
Table 1. Characterization of transgenic mice.
Construct Deletion Transgenic copy numbers mRNA Protein Mouse line
PrPwt 1 1+/0* 1+ Bl6 WT
PrPDF D32–134 70 2
+ 2+ TgF35
PrPDCD D94–134 1 n.d. 0.2
+ Tg1046
PrPDCDs D94–134 D231–254 6 3.5
+ 0.3+ Tg40
PrPDCDs D94–134 D231–254 5 3
+ 0.3+ Tg42
Dpl 1 0+/1* 1* Bl6 Nagasaki
CD_Dpl 126 1.6+/22* 5+/1* Tg1071
PrP_Dpl 180 4+/120* 2+/0.2* Tg1025
PrP_Dpl 220 7+/180* 3+/0.4* Tg1026
PrP mRNA and protein levels are expressed relatively to wild-type mice (+) or, in the case of PrnpNgsk/Ngsk mice, relatively to Dpl expression (*).
doi:10.1371/journal.pone.0006707.t001
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Figure 2. Expression and localization of transgenic proteins. (A) Similar glycosylation patterns of PrPC, PrP_Dpl, CD_Dpl and Dpl. Brain
homogenates were subjected to PNGase F treatment as indicated, and analyzed by Western blotting using anti-PrP mouse monoclonal antibody
POM3 (upper panel) or anti-Dpl mouse monoclonal antibody E2 (lower panel). The spurious band at 20–25 kDa in the 1st lane of the lower panel may
indicate incomplete deglycosylation of Dpl. (B) The glycosylation patterns of full-length PrP, PrPDCD and PrPDCDs are similar. PNGase-treated brain
homogenates were analyzed by Western blotting using anti-PrP mouse monoclonal antibody POM11. (C) protein levels in brain extract of transgenic
mice compared to PrP in BL/6 mice (filled black columns and left ordinate) and compared Dpl in Nagasaki mice (open columns and right y-axis) using
either PrP specific anti bodies POM11 or POM 3 or Dpl specific antibody E2 for western blot. Each column represents the average of 3 mice. (D)
Detergent-resistant membrane (DRM) preparations from transgenic mouse brains were separated by density gradient centrifugation and analyzed by
Western blotting with monoclonal antibody POM3. Significant amounts of PrPC, PrP_Dpl, and CD_Dpl buoyed similarly to flotillin (48 kDa) confirming
localization within DRMs. Non-buoyant fractions may indicate raft disruption or may represent immature protein fractions. (E) Density gradient DRM
preparations of wild-type and anchorless PrP (PrPs), PrPDCD and PrPDCDs transgenic brains analyzed after deglycosylation with PNGase F with
monoclonal antibody POM1. PrP and PrPDCD buoyed similarly to flotillin, whereas PrPs and PrPDCDs (lower band in fraction 13, arrowhead) were never
DRM-associated irrespectively of the presence or absence of wild-type PrP (*). (F) Plasma concentration of prion protein variants. Plasma from wild-
type Prnp+/+; Prnp+/o; Prnpo/o; PrPDCD (Tg1046), PrPDCDs (Tg40; Tg42) and anchorless PrPs (Tg44) mice was studied by ELISA with POM antibodies. PrP
plasma levels were vastly elevated in all transgenic mice expressing anchorless versions of PrP. (G–N) Cerebellar sections immunostained with
antibodies directed against PrP (POM3) (G–J) and Dpl (K–N). POM3 immunoreactivity was seen in the molecular and granule cell layers of wt (G),
PrP
o=o
PrP Dpl (H) and PrP
o=o
CD Dpl (I) mice but was absent, as expected, from Prnp
Ngsk/Ngsk cerebella (J). Cerebellar molecular and granule cell layers are
immunostained with anti-Dpl antibody in PrP
o=o
PrP Dpl (L) PrP
o=o
CD Dpl (M) and Prnp
Ngsk/Ngsk mice (N). No Dpl staining was observed in wt mice (K) Scale
bar 100 mm.
doi:10.1371/journal.pone.0006707.g002
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they all reside in similar membrane microdomains. Therefore,
most aspects of PrP_Dpl and CD_Dpl biogenesis appear to be
similar to those of PrPC. In contrast, both PrPDCDs and PrPs
displayed less buoyancy, suggesting no association with rafts in
agreement with their biogenesis as soluble proteins. We then
prepared DRMs from Tg42 PrP
z=o
DCDs mice coexpressing PrP
C and
PrPDCDs. Fractions were deglycosylated with PNGase F prior to
western blotting. This experiment revealed that coexpression of
wild-type PrP fails to recruit PrPDCDs to DRMs. Upon
pretreatment with phosphatidylinositol-specific phospholipase C
(PI-PLC) the buoyancy of the GPI-anchored PrP variants became
similar to that of their anchorless counterparts (Fig. S2).
Finally, we determined the serum PrP concentration in PrPwt,
PrPDCD, and PrPDCDs mice, as well as in GPI-Tg44 mice
expressing anchorless full-length PrPs [32] (Fig. 2F). Despite
similar PrP levels in brain homogenates, mice expressing
anchorless versions of PrP (PrPs or PrPDCDs) displayed up to 4-
fold higher serum levels. Therefore, PrPDCDs underwent normal
maturation and glycosylation but was predominantly secreted,
similarly to PrPs.
Phenotypes of mice expressing PrP-Dpl chimeric proteins
All transgenic lines (Tg1025; Tg1026; Tg1071) were maintained
in the Prnp+/o or Prnpo/o allelotype (PrP
z=o
PrP Dpl, PrP
o=o
PrP Dpl,
PrP
z=o
CD Dpl and PrP
o=o
CD Dpl), and monitored using a four-degree
clinical score [10]. It has previously been shown that onset and
development of disease correlate with expression levels of Dpl.
Tg(Dpl)28272/ZrchI and (TgN-Dpl)32 mice, which express high
amounts of Dpl, survived only 32 and 60 days respectively [18,19]
whereas mice expressing lower Dpl levels, such as PrnpNgsk/Ngsk
mice [16], showed progressive symptoms of ataxia and were
euthanized according to clinical scoring at $70 weeks of age.
Instead, none of the PrP
z=o
PrP Dpl, PrP
o=o
PrP Dpl, PrP
z=o
CD Dpl and
PrP
o=o
CD Dpl mice showed abnormal behavior even at .100 weeks
of age, and most of them died at 26–35 months of age (Fig. 3A).
This suggests that the presence of amino terminal domains of PrP
reduces the toxicity of Dpl.
Phenotypes of mice expressing anchorless PrPDCDs
proteins
Transgenic lines Tg40 and Tg42, henceforth termed PrP
z=o
DCDs,
and PrP
o=o
DCDs, were monitored using the same clinical score as with
Dpl-PrP chimeric mice. Onset and development of disease caused
by PrPDCD correlated inversely with expression levels of the
transgene and was ameliorated by coexpression of PrPC. Mice
expressing high amounts of PrPDCD survived 35 (Tg1050) or 80
days (Tg1047) in a PrP
z=o
DCD genotype whereas Tg1046 mice, which
express less PrPDCD only developed pathology in the absence of
PrPC and reached an age of 26 days [10]. Despite higher total
expression levels in PrPDCDs than in PrPDCD, even after.60 weeks
none of the PrP
z=z
DCDs, PrP
z=o
DCDs, and PrP
o=o
DCDs from both transgenic
lines Tg40 and Tg42 showed abnormal behavior, and most of them
died at a similarly advanced age as wt mice (Fig. 4A). Therefore,
removal of the membrane anchor prevents the toxicity caused by
deletion of the central domain (CD) of PrPC.
Histological phenotype
Wt, PrP
o=o
PrP Dpl, PrP
o=o
CD Dpl, and Prnp
Ngsk/Ngsk mice were sacrificed
at 100, 200, and 420 days of age, and brains as well as spinal cords
were analyzed histologically. By the age of 200 days these mice
displayed no pathological alterations with the exception of some
Purkinje cells loss in PrnpNgsk/Ngsk mice (data not shown). When
brains of 60 week-old wt (Fig. 3B, F, J), Tg1026 PrP
o=o
PrP Dpl (Fig. 3C,
G, K), Tg1071 PrP
o=o
CD Dpl (Fig. 3D, H, L) and Prnp
Ngsk/Ngsk mice
(Fig. 3E, I, M) were compared, GFAP immunostains (Fig. 3B–I)
showed moderate activation of astrocytes within the molecular layer
of the cerebellum in PrP
o=o
CD Dpl mice (Fig. 3D). No such pathological
changes were seen in PrP
o=o
PrP Dpl (Fig. 3C) and wt mice (Fig. 3B).
White matter pathology characterized by vacuolation and
astrogliosis was seen in the cerebellum (arrows Fig. 3E) and in
the corpus callosum of PrnpNgsk/Ngsk mice (Fig. 3I). None of these
changes were observed in wt, Tg1026 PrP
o=o
PrP Dpl and Tg1071
PrP
o=o
CD Dpl mice (Fig. 3F–H). Transverse semithin sections of spinal
cords (mid-thoracic level, Fig. 3J–M) and of sciatic nerves (Fig. 3O–
R) revealed coarse vacuolar degeneration (white arrowheads) in
myelinated fiber tracts in PrnpNgsk/Ngsk mice and axonal loss (white
arrows, Fig. 3M, R). No such changes were observed in wt,
Tg1026 PrP
o=o
PrP Dpl and Tg1071 PrP
o=o
CD Dpl mice (Fig. 3J–L, O–Q).
Wt, Tg1046 PrP
o=o
DCD, Tg40 PrP
o=o
DCDs, and Prnp
o/o mice were
sacrificed at 23 days and 60 weeks of age, and brains as well as
sciatic nerves were analyzed histologically (Fig. 4). Tg40 PrP
o=o
DCDs
mice of 23 days of age (Fig. 4C, G) displayed no pathological
alterations compared to Tg1046 PrP
o=o
DCD mice which showed
strong cerebellar white-matter astrogliosis (Fig. 4D). Transverse
semithin sections of the sciatic nerve revealed peripheral
neuropathy in Tg1046 PrP
o=o
DCD with axonal loss white arrows
and myelin degeneration white arrowheads (Fig. 4H) but not in wt
(Fig. 4F), PrPo/o (Fig. 4I) or Tg40 PrP
o=o
DCDs (Fig. 4G) at 23 days of
age. No PrPDCDs toxicity was observed also at later time points
(data not shown).
Functional rescue of truncated PrP variants
PrP_Dpl and CD_Dpl did not elicit any clinical or histopath-
ological syndrome in Prnpo/o mice. This may indicate that
PrP_Dpl and CD_Dpl have lost all functional characteristics of
PrP-like proteins. We assessed this possibility by intercrossing
Tg1026 PrP_Dpl and Tg1071 CD_Dpl transgenic mice with the
neurotoxic PrP deletion mutants Tg1046 PrPDCD and TgF35
PrPDF mice [9], whose toxicity can be ameliorated by the
coexpression of full length PrP. The resulting Tg1046 PrP
o=o
DCD
developed first signs of disease at 18–20 days post birth and
reached terminal disease at 2560.7 days (n = 22) of age, as
described previously. Double transgenic Tg10466Tg1071
PrP
o=o
DCD CD Dpl mice survived until 4363.3 days (n = 8), whereas
Tg10466Tg1071 PrPo=oDCD littermates survived 2562.0 days
(n = 11) (Fig. 5A and Table 2). Double-transgenic Tg10466Tg1026
PrP
o=o
DCD PrP Dpl mice survived 3661.3 days (n = 6), as opposed to
2661.7 days (n = 6) for Tg10466Tg1026 PrPo=oDCD littermates
(Fig. 5C and Table 2). A similar trend was also seen in the
transgenic line Tg1025 PrP
o=o
DCD PrP Dpl and in intercrosses of the
PrPDCD lines Tg1047 and Tg1050 (data not shown), with
significant prolongation of survival (ANOVA; p,0.001). TgF35
PrP
o=o
DF mice developed ataxia and were euthanized at 9665.3 days
of age (Fig. 5B, D and Table 2) as described [9]. Double transgenic
TgF356Tg1071 PrPo=oDF CD Dpl mice survived 150612.7 days (n = 8;
Fig. 5B; Table 2), whereas double transgenic TgF356Tg1026
PrP
o=o
DF PrP Dpl mice survived 13964.13 days (n = 11; Fig. 5D;
Table2). In both cases survival was significantly longer (ANOVA;
p,0.001) than for the single transgenic littermates TgF356Tg1071
PrP
o=o
DF and TgF356Tg1026 PrP
o=o
DF . In both paradigms one Prnp
allele sufficed to fully suppress the phenotype of the toxic mutant
(data not shown).
Histological analysis of terminally sick Tg1046 PrP
o=o
DCD mouse
brains revealed astrogliosis both in the corpus callosum (not
shown) and in the cerebellar white matter (Fig. 5E) while TgF35
PrP
o=o
DF mice displayed additional severe cerebellar granule cell
PrP Functional Domains In Vivo
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Figure 3. Survival and histological phenotype of PrP/Dpl chimeric mice. (A) Survival of transgenic mice. The longevity of both PrP_Dpl and
CD_Dpl mice was unaffected by their endogenous Prnp status. All mice survived longer than Nagasaki mice and did not develop clinically apparent
pathologies. Each line represents data derived from $8 individuals. (B–R) Histopathological changes in 60 week old wt (1st column from left),
PrP
o=o
PrP Dpl Tg1026 (2
nd column), PrP
o=o
CD Dpl Tg1071 (3
rd column), and PrPNgsk/Ngsk mice (4th column). Panels B–I represent GFAP immunostains of the
cerebellum (1st row) and of the corpus callosum (2nd row), whereas panels J–M depict paraphenylene diamine-stained semithin sections of the mid-
thoracic spinal cord (3rd row) and sciatic nerve (4th row). PrP
o=o
CD Dpl mice showed mild cerebellar astrogliosis (D), whereas PrP
Ngsk/Ngsk mice had
additional vacuolar white matter changes (arrows) and Purkinje cell loss (E). No pathological changes were seen in Tg1026 PrP
o=o
PrP Dpl (C), Tg1025
PrP
o=o
PrP Dpl (not shown) and wt mice (B). Vacuolar white matter pathology and astrogliosis in the corpus callosum of PrP
Ngsk/Ngsk mice (I) but not in wt
(F), PrP
o=o
PrP Dpl (G) and PrP
o=o
CD Dpl mice (H). Semithin sections revealed coarse vacuolar degeneration of myelinated fiber tracts in PrP
Ngsk/Ngsk mice (M,
R), whereas no such changes were observed in wt (J, O), PrP
o=o
PrP Dpl (K, P) and PrP
o=o
CD Dpl mice (L, Q). Arrows: areas with axonal loss; arrowheads: axons
with degenerated myelin sheaths (M, R). Scale bars: 100 mm in panels B–I; 25 mm in panels J–R.
doi:10.1371/journal.pone.0006707.g003
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(CGC) loss (Fig. 5H). Milder white-matter changes and much less
severe CGC loss were observed in compound Tg10466Tg1071
PrP
o=o
DCD CD Dpl and Tg10466Tg1026 PrP
o=o
DCD PrP Dpl littermates
euthanized at the same age (Fig. 5F–G and 5I–J). Western blot
analysis of brain homogenates indicated that expression levels of
the various transgenic proteins were unchanged in the compound
transgenic mice independently of the respective combination. The
steady-state levels of CD_Dpl exceeded those of PrPDCD PrPDF
and PrPwt (Fig. 5K, M), whereas those of PrP_Dpl and PrPDCD
were similar and much lower than those of PrPDF (Fig. 5L, N).
Although expression of CD_Dpl was higher than that of PrP_Dpl,
and compound PrP
o=o
DCD CD Dpl and PrP
o=o
DF CD Dpl mice displayed
longer survival than PrP
o=o
DCD PrP Dpl and PrP
o=o
DF PrP Dpl mice,
CD_Dpl seemed to be less effective than PrP_Dpl to suppress
cerebellar granule cell loss. This finding may point to a specific
function of the amino proximal regions in suppressing neurode-
generation.
In order to address the functionality of PrPDCDs, we intercrossed
Tg42 PrPDCDs and Tg1046 PrPDCD mice and monitored the
offspring for clinical signs of disease. Tg10466Tg42 PrPo=oDCD were
found to develop first signs of disease at 18–20 days post birth, and
reached terminal disease at 2560.71 days of age (n= 22; Fig. 4A
and Table 2). Double transgenic Tg10466Tg42 PrPo=oDCD DCDs mice
survived for 2561.9 days. Hence there was no significant difference
in survival. All single or double transgenic mice coexpressing PrPC:
Tg10466Tg42 PrPz=oDCD, andTg10466Tg42 PrP
z=o
DCD DCDs survived to
old age without any signs of clinical disease, indicating that PrPDCDs
does not diminish the potential of PrPC to ameliorate PrPDCD
induced toxicity. In contrast, PrPDF and PrPDCD were previously
shown to compete for the rescue effect of PrPC in double transgenic
mice Tg10466TgF35 PrPz=oDCD DF [10]. We therefore conclude that
removal of the lipid anchor from PrPDCD completely abolishes its
neurotoxic properties.
Discussion
The results presented here confirm and extend a recent report
that fusion of the complete amino-terminus of PrP detoxifies Dpl.
Figure 4. Survival and histological phenotype of transgenic mice expressing PrPDCDs. (A) Survival of compound transgenic mice. Survival
curves of mice expressing Tg1046 PrPDCD, Tg42 PrPDCDs or PrPDCD and PrPDCDs (Tg10466Tg42), in the presence or absence of full-length PrP
C. Each line
comprises the number of individuals indicated in Table 2. (B–I) Histopathological changes in 23 days old wt (B, F), Tg40 PrP
o=o
DCDs, (C, G), and terminal
Tg1046 PrP
o=o
DCD mice (D, H) and Prnp
o/o mice (E, I); B–E are GFAP immunostains of cerebellum, F–I are transverse semithin sections of sciatic nerves.
Severe astrogliosis and vacuolar changes (arrows) are observed in cerebellar white matter of Tg1046 PrP
o=o
DCD mice (D) as described [10]. No
pathological changes are seen in Tg40 PrP
o=o
DCDs (C) wt (B) and Prnp
o/o mice (E). Transverse semithin sections of the sciatic nerve (F–I) reveal mild axonal
loss (arrows) and coarse vacuolar degeneration in myelinated fiber tracts in Tg1046 PrP
o=o
DCD mice (H) while no such changes are observed in wt (F),
Tg40 PrP
o=o
DCDs (G) and Prnp
o/o mice (I). White arrowheads: axons with degenerated myelin sheaths. Scale bars: 200 mm (B–E) or 20 mm (F–I).
doi:10.1371/journal.pone.0006707.g004
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Figure 5. Survival of compound transgenic mice. Survival of compound transgenic mice derived from intercrosses between the transgenic lines
described above. (A–D) Survival curves of mice lacking PrPC and expressing various transgenes (PrPDF, PrPDCD, CD_Dpl, PrP_Dpl) as indicated by the
subscripts. Each line summarizes the survival animals with the respective genotype (group size: 6–16 as indicated). (E–J) Comparison of
histopathological phenotypes in terminally sick PrP
o=o
DCD and PrP
o=o
DF mice with their respective age matched compound littermate transgenic mice. All
pictures show GFAP-immunostained cerebellar sections at identical magnification. Terminally sick Tg1046 PrP
o=o
DCD mice showed astrogliosis both in
cerebellar cortex and white matter (E). Milder changes were present in Tg10466Tg1071 PrPo=oDCD CD Dpl (F) and Tg10466Tg1026 PrP
o=o
DCD PrP Dpl mice (G).
Subtotal granule cell loss associated with severe astrogliosis was seen in the cerebellum of TgF35 PrP
o=o
DF mice (H). However, granule cell loss and
astrogliosis was less severe in TgF356Tg1071 PrPo=oDF CD Dpl mice (I) and almost absent from TgF356Tg1026 PrP
o=o
DF PrP Dpl mice (J). Scale bar = 5 mm. (K–
N) Brain expression of PrPC and transgenic PrP deletion mutant as well as PrP/Dpl fusion proteins. Specific bands are indicated with arrowheads (K)
The expression of CD_Dpl was higher than that of PrPDCD and PrP
C. Lanes 1–3 represent a serial dilution of a Tg10466Tg1071 PrPo=oDCD CD Dpl mouse
compared to a PrP
z=o
DCD CD Dpl mouse (lanes 4–6). (L) PrP_Dpl expression is similar to that of PrPDCD and significantly lower than that of PrP
C. Lanes 1–3
represent serial dilutions of Tg10466Tg1026 PrPz=oDCD PrP Dpl mice. The asterisk indicates a carboxy terminal fragment formed from wild-type PrP
C. (M)
Indirect comparison indicates similar PrPDF and CD_Dpl levels in TgF356Tg1071 PrP
o=o
DF CD Dpl mice which were higher than those of PrP
C. Lanes 1–4
depict a serial dilution of a TgF356Tg1071 PrPz=oDF CD Dpl mouse. (N) PrP_Dpl was less abundant than PrPDF in TgF356Tg1026 PrP
o=o
DF PrP Dpl and
TgF356Tg1026 PrPz=oDF PrP Dpl mice. Lanes 1–3 depict a serial dilution of a TgF356Tg1026 PrP
o=o
DF PrP Dpl mouse compared to a TgF356Tg1026
PrP
z=o
DF PrP Dpl mouse (lanes 4–6). All brain homogenates were treated with PNGase F, and replica western blots were decorated with antibodies POM1,
POM3, and POM11 as indicated below each blot.
doi:10.1371/journal.pone.0006707.g005
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Tg(PrPN-Dpl) mice expressing a fusion protein consisting of amino
acids 1–124 of PrP and amino acids 58–179 of Dpl failed to show
Dpl typical neurological disorder and were able to prolong the
onset of ataxia in mice with exogenous Dpl expression [24]. By
generating chimeric proteins that contain either the entire amino-
terminus of PrP linked to the carboxy-terminus of Dpl (PrP_Dpl)
or the central domain of PrP alone (CD_Dpl), we found specific
domains within the amino-terminus of PrP that are involved in the
detoxification of Dpl in two distinct brain regions and cell types.
While PrP_Dpl showed no signs of cerebellar granule cell
degeneration for at least 60 weeks, PrP
o=o
CD Dpl mice displayed mild
astrogliosis within the CGC layer. This may point to some residual
neurotoxicity of CD_Dpl. In contrast, white matter degeneration was
observed in Dpl-expressing Ngsk mice yet was not seen in mice
expressing either of the two transgenes, PrP_Dpl and CD_Dpl. Since
leukoencephalopathy is the major life-shortening pathology associat-
ed with expression of truncated PrP and Dpl [10,33], both addition of
the whole amino-terminus, or addition of the central domain alone
resulted in a normal life expectancy in transgenic mice.
In addition to detoxifying Dpl, chimeric fusion proteins were
able to partially antagonize the toxic effects of the PrP deletion
mutants PrPDF and PrPDCD. While PrP_Dpl was able to
antagonize cerebellar granule cell loss in PrPDF mice, CD_Dpl
was not. Cerebellar white matter gliosis was milder in both
PrP
o=o
DF CD Dpl and PrP
o=o
DF PrP Dpl mice. This lends further support to
the conclusion that distinct domains within PrP exert neurotrophic
functions in a variety of brain regions and cell types.
We have excluded that differences in expression level were
responsible for the observed effects: Western blotting with antibody
POM3 [31], which recognizes a domain common to both
transgenes, showed a higher expression for CD_Dpl than for
PrP_Dpl. All transgenic constructs were expressed using the same
backbone, thereby reducing the likelihood of differential expression
in distinct cell types. Thus the cell-specific effects of the different
transgenes appear to be related to their structural features rather
than to the levels or tissue-specific patterns of their expression.
Despite sequence homologies of ,20%, the carboxy terminal
domains of Dpl and PrP have very similar folding patterns of the
respective carboxy proximal regions, whereas their amino proximal
portions are much less structured [20,34,35]. Hence the selective
permutations of the less structured domains of the two proteins
performed here are not very likely to alter the overall global fold of the
resulting fusion proteins. We found that both PrP_Dpl and CD_Dpl
underwent correct intracellular sorting and posttranslational processing
(Fig. 2A, C). Furthermore, in none of the transgenic mice (including the
lines expressing the highest levels of transgene) did we detect any
spontaneous formation of PK-resistant transgenic protein or PrP
aggregates by Western blotting and histology (data not shown).
Further evidence for specific differences in the function of PrPC
comes from the previous studies on transgenic mice expressing
PrPC in a cell-type specific manner. While cerebellar granule cell
loss in PrPDF mice was reversed by neuronal expression of PrP,
white matter degeneration was rescued by myelin-specific
expression of PrP [36].
Cell-specific requirements for distinct PrP domains might
explain the discrepancies regarding the domains reported to be
involved in cytotrophic functions. Several studies suggest that the
octapeptide repeat region is crucially linked to the neuroprotective
functions of PrPC [37,38,39]. On the other hand, a feature
common to all the toxic PrP deletion mutants is the lack of the
central domain (encompassing at least residues 105–125) within
PrPC. This in turn points to a role of the central domain of PrPC.
The results presented here may help clarifying this controversy.
The central domain (aa 94–134) appears to be crucial for myelin
maintenance, while other domains within the amino terminus (aa
23–94) may be required for neuroprotection. Residues 23–94
consists of the amino-terminal charged cluster (aa 23–28) involved
in endocytosis and of the octapeptide repeat region associated with
neuroprotection via anti-oxidative function and copper binding (aa
50–90) [37,39,40]. It was initially reported that amino acids 23–88
are needed to fully suppress neurotoxicity on Purkinje cells [41],
yet it was later shown that the octapeptide repeats are dispensable
for this function. This suggests that the charge cluster may be more
relevevant for the neuroprotection of Purkinje cells [24] that for
other cell types. It is less likely that toxic domains within the
amino-terminus of Dpl in CD_Dpl may be responsible for the
observed residual neurotoxicity, since earlier studies showed that
the proximate cause of cerebellar granule cell degeneration is not
the amino terminus of Dpl, but rather its carboxy terminus [42].
PrPC was reported to inhibit the NR2D subunits of the NMDA
receptor complex, and Prnpo/o hippocampal neurons display
increased neuronal excitability and enhanced glutamate excito-
toxicity [43]. It will be interesting to study whether chimeric PrP/
Dpl proteins exert PrPC like functional regulation of the NMDA
receptor and whether central domain, octapeptide repeat region
or amino-terminal charged cluster are involved in this function.
Table 2. Survival of compound transgenic mice.
Crosses Number of animals Genotype Average survival [days] Standard deviation of mean [days] Significance
Tg1046 22 PrP
o=o
DCD
25.2 0.7
Tg10466Tg1071 8 PrPo=oDCD CD Dpl
42.9 3.3 *** p,0.001
Tg10466Tg1026 6 PrPo=oDCD PrP Dpl
36.3 1.3 *** p,0.001
TgF35 15 PrP
o=o
DF
95.6 5.3
TgF356Tg1071 8 PrPo=oDF CD Dpl
150.1 12.7 *** p,0.001
TgF356Tg1026 11 PrPo=oDF PrP Dpl
139.1 4.1 *** p,0.001
Tg1046 7 PrP
o=o
DCD
27.3 0.6
Tg10466Tg42 10 PrPo=oDCD DCDs
24.8 0.6 Ns p.0.05
Mice of various genotypes were housed and monitored according to a 4-degree clinical score system. Terminally sick animals were euthanized. Mean survivals of single-
transgenic littermates were compared to double transgenic mice and statistical significance of difference was tested by ANOVA.
doi:10.1371/journal.pone.0006707.t002
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It was suggested that homodimerization of PrPC mediates the
transduction of extracellular signals [44,45,46]. The toxicity of
truncated PrP and Dpl is counteracted by overexpression of full-
length PrPC [9,10,18,19] and exacerbated by removal of the
endogenous Prnp gene, suggesting that PrPC and its variants
compete for a common interacting molecule. The PrP/Dpl fusion
proteins appear to partake in this competition as well, as both
CD_Dpl and PrP_Dpl prolonged survival of PrP
o=o
DCD and PrP
o=o
DF
mice. Perhaps the CD region is responsible for stringent protein-
protein interactions, whereas the structured carboxy termini of
PrP and Dpl allow for more relaxed interactions and are therefore
interchangeable. Such interactions might also include the
formation of functionally relevant homodimers or homooligomers
[47]. The residues 113–128 of PrP mediate interaction of PrP with
stress inducible protein 1 (STI) [48] and heparan sulfate [49]. The
incompleteness of the rescue in all tested paradigms of
PrP
o=o
DCD CD Dpl, PrP
o=o
DCD PrP Dpl, PrP
o=o
DF CD Dpl and PrP
o=o
DF PrP Dpl
mice may relate to insufficient amounts of the respective fusion
proteins, or possibly to reduced affinity for their binding partners.
In addition to the findings described above, we extended our
analysis of functional domains within PrP to those determining the
localization of the protein. Mice expressing anchorless PrP
accumulate high titers of prions and protease-resistant PrP when
challenged with scrapie [32,50], yet develop only subtle pathol-
ogies [51]. Here, anchorless PrPDCDs was expressed to high levels
in transgenic mice, and was very efficiently secreted into the
extracellular space of brain and in serum as a mature, fully
glycosylated soluble form [52]. Although the deletion within
PrPDCDs was identical to that of the neurotoxic membrane
anchored PrPDCD, it did not induce any pathology in transgenic
mice, irrespectively of the presence or absence of full-length PrPC.
Since the total concentration of PrPDCDs in brain homogenates
was as high as that of PrPDCD, and even higher than that of
PrPDCD in the serum, lack of toxicity was unrelated to its
expression level. Also, PrPDCDs failed to influence the survival of
PrPDCD mice coexpressing PrP
C, confirming that it exerts neither
beneficial nor detrimental effects on the central nervous system.
PrPDCDs did not localize to detergent-resistant membrane (DRM)
fractions, even when wild-type PrPC was coexpressed. This
observation suggests that the genetic interaction between PrPC
and its neurotoxic variants may physically necessitate membrane
anchoring of all relevant partners. In contrast, soluble-dimeric prion
protein (PrP-Fc2) was found to translocate to the DRM compart-
ment and to associate with PrPSc upon prion infection of mice
coexpressing PrPC and PrP-Fc2 [51]. In this context, it may be of
interest to study the localization of PrPDCDs in prion infected mice.
In conclusion, the above findings indicate that (1) the amino
proximal domain of PrP contains minimal elements that are
necessary and sufficient for PrP function, that (2) distinct domains
within the amino-terminus of PrP exert site- and/or cell-specific
functions, and that (3) GPI membrane anchoring is mandatory for
exerting said function. The understanding of the physiological and
pathophysiological functions of the prion protein will benefit from
functional analyses of the proteinaceous [48] and non proteina-
ceous [49] constituents interacting with PrP and its variants.
Finally, it will be of particular interest to explore whether the
phenomena studied here share functional and molecular aspects
with the neurotoxicity observed in prion diseases [53].
Materials and Methods
Ethics Statement
All mice were maintained under specific pathogen-free (SPF)
conditions. Housing and experimental protocols were in accor-
dance with the Swiss Animal Protection Law and in compliance
with the regulations of the Veterinaeramt, Kanton Zurich.
Construction of the transgenes
The coding region of murine Prnp and Prnd gene were analyzed
using DNAMAN software (Lynnon BioSoft, Canada), and hydropho-
bicity plots were generated using a window of 9 amino acid residues.
The regions identified in these plots were used to define the CC, CD
and HC domains. The chimeric fusion proteins of PrP and Dpl were
designed such that their hydrophobicity characteristics would mimic
that of wild-type PrP. Based on pPrPHG [25], a PmeI/NheI fragment
was subcloned in the pMECA [54] backbone. To create the CD_Dpl
cDNA, mouse genomic cDNA was used as template to obtain two
PCR fragments with primer sets JP1 (59-ATA ATA ATG CAT ACC
ACC ATG AAG AAC CGG CTG GGT AC)/JP2 (59-TAC TGC
CCC AGC TGC CGC AGC CCC TGC CAC ATG CTT GAG
GTT GGT TTT TGG TTT GCT GGG CTT GTT CCA CTG
ATT ATG GGT ACC CCC TCC CCG GCC TTG CTT GAT
GAA GG) and JP3 (59-CCT CAA GCA TGT GGC AGG GGC
TGC GGC AGC TGG GGC AGT AGT GGG GGG CCT TGG
TGG CTA CAT GCT GGG GAG CGC CGT GAG CAG GCC
CAT GAA GCT GGA CAT CGACTT TGG )/JP4 (59-ATA ATA
ATG CAT TTA CTT CAC AAT GAA CCA AAC). The two initial
products were fused in a third PCR with the flanking primers JP1 and
JP4. This product was digested with NsiI and ligated to the NsiI sites of
the pMECA vector containing the pPrPHG subcloned PmeI/NheI
sequence into which a second NsiI site had been engineered. After
confirming insertion with the correct orientation, the insert was cloned
back into the pPrPHG backbone using the PmeI/NheI sites.
PrP_Dpl was created based on the plasmid pPrPHG [25]. A
fragment (480 bp) was amplified using the primers pE2* (59-CAA
CCG AGC TGA AGC ATT CTG CCT)/X2 (59-CCT GCT
CAC GGC GCT CCC CAG CAT G) containing sequence
information from Exon3 to codon 132/133 of the murine PrP. In
a second PCR using genomic DNA as template and primers X3
(59-GGG AGC GCC GAC ATC GAC)/X4 (59-AAA GAA TTC
CAC AAT TCT TAC TTC ACA ATG) a fragment (360 bp)
containing codon 68 until polyadenylation site of Dpl was
amplified. After purification both fragments were cut with HaeII
mixed and directly ligated into the pCR-Blunt II-Topo vector.
The transgene was then excised with AgeI/EcoRI and, after
blunting the 39 EcoRI sites, ligated into the original AgeI/BbrPI site
of pPrPHG. The presence of the new insert was confirmed by
restriction analysis using SmaI.
PrPDCDs was generated using the pMECA PmeI/NheI subclone
pPrPHG previously described [10]. The oligonucleotide primers
dCDSol59 (59-CCT ATT ACG ACGGGAGAAGAT CCT GAT
GAA CCG TGC TTT TCT CCT CC-39) dCDSol39 (59- GGA
GGA GAA AAG CAC GGT TCA TCA GGA TCT TCT CCC
GTC GTA ATA GG-39), each complementary to opposite strands
of the vector, were extended during temperature cycling by
PfuTurboH DNA polymerase. On incorporation of the oligonucle-
otide primers, a mutated plasmid containing staggered nicks was
generated. After temperature cycling and treatment with DpnI to
digest the parental DNA template and select for the desired DNA
construct, the nicked vector DNA incorporating the mutations was
transformed into E. coli. Clones were picked and sequenced. Finally
the PmeI/NheI fragment containing the desired point mutation was
religated into the pPrPHG vector as described before [10].
Generation, Identification, and Maintenance of
Transgenic Mice
The pPrPHG plasmids containing the PrP or Dpl coding
sequences were propagated in E. coli XL1 blue, the minigene
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excised with NotI and SalI, and processed as described [25].
Pronuclear injections into fertilized oocytes were carried out as
described [55]. Transgenes on a Prnpo/o background were identified
by PCR using the exon 2 primer pE2* (59-CAA CCG AGC TGA
AGC ATT CTG CCT) and the exon 3 primer Ubl floxed Dpl (59-
CTC GCT GGT GGA GCT TGC TAT C) resulting in a PCR
product of 618 bp for CD_Dpl and 670 bp for PrP_Dpl or pE2*
and exon 3 primer Mut217 (59-CCT GGG ACT CCT TCT GGT
ACC GGG TGA CGC) resulting in a PCR product of 619 bp.
PCR analysis in order to verify the outbreeding of the Prnp+ allele
was carried out using primers P10 (Prnp exon 3, 59-GTA CCC ATA
ATC AGT GGA ACA AGC CCA GC), 39NC (non-coding region
at 39 of exon 3, 59-CCC TCC CCC AGC CTA GAC CAC GA),
and P3 (neoR gene, 59-ATT CGC AGC GCA TCG CCT TCT
ATC GCC); P10 and 39NC gave an 560 bp signal for the Prnp+
allele, and P3 and 39NC gave a 362 bp product for the Prnp0 allele.
Alternatively, to test for the presence or absence of the Prnp+ allele
an additional PCR was performed using primers P2 (Prnp int 2, 59-
ATA CTG GGC ACT GAT ACC TTG TTC CTC AT) and
P10rev (reverse complementary of P10 59-GCT GGG CTT GTT
CCACTGATTATGGGTAC) giving a product of 352 bp for the
Prnp+ allele. In order to distinguish between transgenic mice
expressing PrPDCD and PrPDCDs, two separate PCR reactions were
performed using primers pE2* and pdCDrev (59-GGA GGA GAA
AAG CAC GGT GCT GCT) yielding a diagnostic amplicon of
666 bp, or using pE2* and pdCDsrev (59-GGA GGA GAA AAG
CAC GGT TCA TCA) yielding a diagnostic amplicon of 666 bp.
Q-PCR to determine genomic copy numbers
Total genomic DNA was prepared from mouse tails after PK
digestion and purified according to standard procedures. Copy
numbers were assessed by Taqman PCR using 2 ng of total
genomic DNA and primer pairs CD Sonde59 (59-GGA GGG
GGT ACC CAT AAT) and CD Sonde39 (59- GCG CTC CCC
AGC ATG TAG) on C57Bl6, Tga20, Prnpo/o, Tg1025, Tg1026
and Tg1071 mice. For determination of copy numbers of Tg40,
Tg42 primer pairs p60 (59-CGC TAC CCT AAC CAA GTG T)
and p61 (59-GAT CTT CTC CCG TCG TAA T) were used. To
standardize Taqman PCR on GAPDH using primers GAPDH up
(59-CCA CCC CAG CAA GGA GAC T) and GAPDH down (59-
GAA ATT GTG AGG GAG ATG CT) was done in parallel.
mRNA analysis
Total brain RNA was isolated in Trizol (Life Technologies),
purified and DNase treated according to the manufacturer’s
manual (Roche). After reverse transcription (Geneamp; Roche)
cDNA was used for Taqman PCR using primer pairs Dpl Taq59
(59-CTA CGC GGC TAA CTA TTG)/Dpl Taq39 (59-CGC
CGG TTG GTC CAC) and PrP Taq59 (59-CAG TGG AAC
AAG CCC AGC)/PrP Taq39 (59-CCC CAG CAT GTA GCC
ACC). To standardize expression levels GAPDH using primers
GAPDH up (59-CCA CCC CAG CAA GGA GAC T) and
GAPDH down (59-GAA ATT GTG AGG GAG ATG CT) and
18S rRNA using primers 18S fw (59-GTA ACC CGT TGA ACC
CCA TT) and 18S rc (59-CCA TCC AAT CGG TAG TAG CG)
were used. Taqman PCR using SYBR-green (Roche) and
determination of DDCT-values were done on a Applied
Biosystems 7900 device. As control for possible DNA contamina-
tion, DNase-treated RNA from wt and tg mice that had not been
reversely transcribed was used.
Western blot analysis
Brain hemispheres were homogenized in 7 vol PBS, 0.5%
Nonidet P-40, and 0.5% deoxycholate and the solution was
centrifuged 5 min in an Eppendorf centrifuge. For deglycosyla-
tion, up to 50 mg denatured total protein were incubated at 37uC
for 4 h with 500 U PNGase F (New England Biolabs) according to
the manufacturer’s instructions. The protease inhibitors Pefabloc
(1 mg/ml), Leupeptin (10 mg/ml), Pepstatin (10 mg/ml), Aprotinin
(1 mg/ml) (all from Boehringer, Mannheim), and 0.5 mg/ml
EDTA were added. After electrophoresis of protein samples
through 12% SDS-polyacrylamide gels, samples were transferred
to nitrocellulose membranes (Schleicher & Schuell) and incubated
with mouse monoclonal anti-PrP antibodies POM1, POM3 and
POM11 [31], followed by incubation with peroxidase-labeled anti-
mouse antiserum (1:2500; Amersham) and developed with the
ECL detection system (Pierce). Antibody incubations were
performed in 1% Top Block (Juro) in Tris-buffered saline-Tween
(TBS-T) for 1 h at room temperature or overnight at 4uC.
Flotation assays
Flotation of detergent insoluble complexes was performed as
described [56]. Appropriate brain homogenates were extracted for
2 h on ice in cold lysis buffer (150 mM NaCl, 25 mM Tris-HCl,
pH 7.5, 5 mM EDTA, 1% Triton X-100; total protein: 1 mg in
1.6 ml. Extracts were mixed with two volumes (3.2 ml) of 60%
OptiprepH (Nycomed) to reach a final concentration of 40%. All
lysates were loaded at the bottom of Beckman ultracentrifuge
tubes. A 5–30% OptiprepH step gradient in TNE (150 mM NaCl,
25 mM Tris-HCl, pH 7.5, 5 mM EDTA) was then overlaid onto
the lysate (8.4 ml of 30% OptiprepH and 3.6 ml of 5%
OptiprepH). Tubes were centrifuged for 24 h at 4uC in a TLS55
Beckman rotor at 100,000 g. Fractions (1 ml) were collected from
the top of the tube and processed for immunoblotting and
visualization with anti-PrP antibody POM3 [31], anti-flotillin 1,
and anti-GAPDH antibody (both BD Transduction Laboratories).
In order to release GPI anchored proteins from membranes, brain
homogenates were treated for 2 h at 37uC with 10 U/ml
Phospholipase C (PI-PLC from Sigma) as described [57].
ELISA
PrP ELISA was performed as described in [58] 96-well plates
(Nunc-Immuno Maxisorb; prod. no. 439454) were coated with
50 mL per well of POM1 (2 mg/ml, 1:5000 in 0.1 M sodium
carbonate buffer pH 9.6 [1.58 g Na2CO3+2.94 g NaHCO3 in
500 ml H2O]) over night at 4uC. All following incubation steps
were made at room temperature. The plates were washed by
immersing them 4–5 times in PBS with 0.1% Tween-20 (PBST).
Plates were then incubated with 100 mL per well of blocking buffer
(5% Top-Block in PBST) for two hours. A 1:3 dilution of
recombinant murine PrP (rmPrP) (starting from 50 ng/ml) was
used for a standard curve. Blood plasma from respective mice was
diluted appropriately in sample buffer (1% Top-Block in PBST)
and incubated for 1 h. Then, plates were washed 4–5 times in
PBST and incubated with biotin-labeled POM2 (1 mg/ml, 1:5000
in sample buffer, 100 mL per well) for 1 h. Plates were washed 4–5
times and incubated with avidin-HRP (1 mg/ml, 1:1000 in sample
buffer, 100 mL per well) for 1 h followed by another round of
washing, 4–5 times in PBST and 2–3 times with PBS alone.
Chromogenic substrate (Biosource, prod. no. SB02, 50 mL per
well) was applied for up to 10 min. The reaction was stopped with
0.5 M H2SO4 and absorbance was read at 450 nm.
Clinical scoring and observation
Mice were examined once weekly for clinical signs as described
previously [10]. Mice were euthanized when they reached a score
of 3.5 or higher. Statistical significance was assessed as indicated.
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Morphological analyses
Brains, spinal cords and sciatic nerves were removed and fixed
in 4% formaldehyde in PBS, pH 7.5, paraffin embedded, and cut
into 2–4 mm sections. Sections were stained with hematoxylin-
eosin (H&E), Luxol-Nissl (myelin and neurons), and commercial
antibodies to GFAP (glial fibrillary acidic protein; activated
astrocytes), MBP (myelin basic protein), NF200 (neurofilament
200), IBA1 (microglia) and SAF84 (PrPSc aggregates). For semithin
sections and electron microscopy mice were perfused with ice-cold
4% PFA/3.9% glutaraldehyde. Spinal cord tissues were removed,
immersed in the same solutions, and kept in Phosphate buffer at
4uC until processing. Tissues were embedded in Epon, and
semithin sections were stained with toluidine blue and para-
phenylene diamine. Frozen sections for POM3 and Dpl staining
were blocked with M.O.M Mouse IgG Blocking Reagent (Vector
Laboratories) stained with anti Dpl GX-2D10-B1 (Dpl) or POM3
(soluble cellular PrP). Detection was achieved using both Goat anti
Mouse AP and Donkey anti Goat AP (Jackson) with alkaline
phosphatase fast red.
Supporting Information
Figure S1 Characterization of transgenic mice (A) Gene copy
numbers per haploid genome in transgenic lines as determined by
genomic Q-PCR. (B) relative mRNA level in brain extracts of
transgenes compared to PrP mRNA in C57BL/6 mice (filled black
columns and left y-axis) and compared Dpl mRNA in PrnpNgsk/Ngsk
mice (open columns and right y-axis) using either PrP or Dpl
specific primer sets for Q-PCR. Each column represents the
average of 3 mice.
Found at: doi:10.1371/journal.pone.0006707.s001 (0.55 MB TIF)
Figure S2 Characterization of membrane anchored and PI-PLC
treated transgenic proteins. Density gradient DRM preparations of
wild-type, PrP GPI anchorless (PrPs), PrPDCD and PrPDCDs
transgenic brains analyzed after PI-PLC treatment and deglyco-
sylation with PNGase F with monoclonal antibody POM1. After
PI-PLC treatment PrP and PrPDCD had similarly buoyancy like
PrPs and PrPDCDs whereas flotillin a non GPI-anchored DRM
associated protein still was found in fractions with higher buoyancy
indicating the intactness of the DRMs.
Found at: doi:10.1371/journal.pone.0006707.s002 (0.84 MB TIF)
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